EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology

Détails

ID Serval
serval:BIB_BD86E9565411
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology
Périodique
European Journal of Cancer Supplements
Auteur(s)
Wicka  Wolfgang, van den Bentb  Martin, Vechtc  Charles, Brandesd  Alba, Lacombee  Denis, Gorliae  Thierry, Allgeiere  Anouk, Baumertf Brigitta G., Soffiettig  Riccardo, Sansonh  Marc, Karimi  Abul B.M.F., Mirimanoffj  Réne-Olivier, Taphoornc  Martin, Krosb  Max, Hegij  Monika, Stuppj  Roger
Collaborateur(s)
EORTC Brain Tumor Group
ISSN
1359-6349
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
10
Numéro
Suppl. 1
Pages
20-26
Langue
anglais
Notes
EORTC 50 Years of Progress Against Cancer (1962-2012)
Résumé
Over the past decade a series of trials of the EORTC Brain Tumor Group (BTG) has substantially influenced and shaped the standard-of-care of primary brain tumors. All these trials were coupled with biological research that has allowed for better understanding of the biology of these tumors. In glioblastoma, EORTC trial 26981/22981 conducted jointly with the National Cancer Institute of Canada Clinical Trials Group showed superiority of concomitant radiochemotherapy with temozolomide over radiotherapy alone. It also identified the first predictive marker for benefit from alkylating agent chemotherapy in glioblastoma, the methylation of the O6-methyl-guanyl-methly-transferase (MGMT) gene promoter. In another large randomized trial, EORTC 26951, adjuvant chemotherapy in anaplastic oligodendroglial tumors was investigated. Despite an improvement in progression-free survival this did not translate into a survival benefit. The third example of a landmark trial is the EORTC 22845 trial. This trial led by the EORTC Radiation Oncology Group forms the basis for an expectative approach to patients with low-grade glioma, as early radiotherapy indeed prolongs time to tumor progression but with no benefit in overall survival. This trial is the key reference in deciding at what time in their disease adult patients with low-grade glioma should be irradiated.
Future initiatives will continue to focus on the conduct of controlled trials, rational academic drug development as well as systematic evaluation of tumor tissue including biomarker development for personalized therapy. Important lessons learned in neurooncology are to dare to ask real questions rather than merely rapidly testing new compounds, and the value of well designed trials, including the presence of controls, central pathology review, strict radiology protocols and biobanking. Structurally, the EORTC BTG has evolved into a multidisciplinary group with strong transatlantic alliances. It has contributed to the maturation of neurooncology within the oncological sciences.
Open Access
Oui
Création de la notice
25/10/2012 17:43
Dernière modification de la notice
09/05/2019 0:33
Données d'usage